The companies of the spinal muscular atrophy (SMA) treatments ‘Spinraza’ and ‘Evrysdi’ failed to conclude drug pricing negotiations for their drugs within the deadline and began extended negotiations.

As a result, Spinraza reimbursement extension and Evrysdi’s new listing will only be possible in October at the earliest.

According to industry sources, the reason for the delay in negotiations for the two drugs is known to be the differences in opinions between the companies and the authorities on the Expenditure Cap that should be set, which is a type of Risk Sharing Agreement (RSA) scheme that is applied to drugs eligible for reimbursement through the pharmacoeconomic evalua